Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants

Relebactam is a novel class A and C β-lactamase inhibitor that is being developed in combination with imipenem-cilastatin for the treatment of serious infections with Gram-negative bacteria. Here we report on two phase 1 randomized, double-blind, placebo-controlled pharmacokinetics, safety, and tole...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Antimicrob Agents Chemother
Asıl Yazarlar: Rhee, Elizabeth G., Rizk, Matthew L., Calder, Nicole, Nefliu, Marcela, Warrington, Steven J., Schwartz, Michael S., Mangin, Eric, Boundy, Keith, Bhagunde, Pratik, Colon-Gonzalez, Francheska, Jumes, Patricia, Liu, Yang, Butterton, Joan R.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society for Microbiology 2018
Konular:
Pharmacology
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6125551/
https://ncbi.nlm.nih.gov/pubmed/29914955
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00280-18
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller